April 02, 2026

Low-Dose Apixaban Cuts Superficial Thrombosis Risk

Extended anticoagulation lowered symptomatic superficial vein thrombosis in patients with provoked venous thromboembolism.

Conexiant

April 01, 2026

FDA Approves Lilly’s Foundayo Oral GLP-1 Pill

The newly approved therapy offers a noninjectable option that can be taken at any time of day without food or water restrictions.

Conexiant

April 01, 2026

Medical Oddities: Pig Semen, Meet Eye Drops

Evolution, sex, soil, and diets—this lineup covers a little bit of everything.

Conexiant

April 01, 2026

Evolocumab Reduced CV Events in Diabetes

Subgroup analysis of the VESALIUS-CV trial supports earlier intensive lipid lowering

Conexiant

April 01, 2026

Tirzepatide Linked to Lower Cardiorenal Events

Researchers evaluate expanded six-component outcome in high-risk patients with diabetes

Conexiant

April 01, 2026

BMI Patterns in ILD Outcomes Examined

Meta-analysis links higher body mass index to lower mortality and slower lung function decline in interstitial lung disease

Conexiant

April 01, 2026

Prednisolone Linked to Metabolic Benefits

A randomized crossover trial found slower bone turnover and no safety differences compared with standard hydrocortisone regimens

Conexiant

March 31, 2026

FDA Monthly Preview: Key April Decisions to Watch

Several high-stakes FDA decisions across multiple specialties are expected this month.

Conexiant

March 31, 2026

Sudden Death Trajectories in HFpEF, HFmrEF

Clinical changes before death overlap across outcomes

Conexiant

March 30, 2026

Side Effects: Variety Is Overrated

The organ you forgot, the cells that age unevenly, the AI that admits ignorance, and the diet advice that sounds wrong but isn't: medicine's next moves are hiding in plain sight.

Conexiant